- CARBOGEN AMCIS and a Japanese partner will co-invest over CHF 25 million to expand Swiss API manufacturing sites.
- The upgrades will support commercial production of an antibody-drug conjugate (ADC) drug linker, with completion expected by 2027.
CARBOGEN AMCIS, a Switzerland-based CDMO specialising in pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing, has announced a joint investment of more than CHF 25 million with a long-standing Japanese customer. The funds will be used to expand manufacturing infrastructure at its Aarau and Neuland sites in Switzerland.
The investment aims to support production of a drug linker for a commercial antibody-drug conjugate (ADC), as demand for these complex therapies grows globally. Enhancements include the installation of 850-litre reactors and 0.4 m² agitated filter dryers at both locations. Work at the Aarau site is scheduled for completion by Q1 2027, while the Neuland site is expected to be completed by Q3 2027.
The co-investment follows a similar collaboration between the two companies in April 2021 to extend CARBOGEN AMCIS’ Bubendorf site. According to the company, the current initiative further strengthens their long-term partnership and shared growth strategy.
“This expansion demonstrates our ability to scale alongside our customers, responding to the increasing demand for complex and high-value compounds such as ADC drug linkers,” said Stephan Fritschi, CEO at CARBOGEN AMCIS.
The company stated that the upgrades will ensure compliance with cGMP and international regulatory standards, while enhancing operational excellence in handling highly potent compounds. These improvements also position the organisation to maintain its contract manufacturing capabilities for advanced therapies.
Stay ahead of trends and best practices
